Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Finds Backup For Aricept In Medivation’s Dimebon

This article was originally published in The Pink Sheet Daily

Executive Summary

Medivation Alzheimer’s candidate is unique for its disease-modifying potential.
Advertisement

Related Content

Almost All Hopes Dashed For Pfizer/Medivation's Dimebon
Prospects For Pfizer/Medivation's Dimebon Dashed By Phase III Flop
Prospects For Pfizer/Medivation's Dimebon Dashed By Phase III Flop
The Year Ahead For Generic Drugs: The Calm Before The Storm
Whatever Works – Or Might: Pfizer/Wyeth Likely To Keep Both Alzheimer’s Bets
Alzheimer’s Player Satori Wades Into Fray With Mystery Technology – And $22 Million
Industry Roundtable: Neurotech Execs Discuss Innovation, Challenges, Next Steps
Targacept’s AstraZeneca Deal Down, Not Out
Pfizer Goes Deeper Into Alzheimer’s Market With Medivation Deal
Bristol And Pfizer Team Up To Develop Anticoagulant Apixaban In $1 Billion Deal

Topics

Advertisement
UsernamePublicRestriction

Register

PS068421

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel